[Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)
Filed with TSE · · 2 pages · English
Summary by 6ix AI
StemRIM Inc. has issued a notice regarding the recognition of non-operating income from subsidy income related to a project in regenerative medicine and gene therapy. This initiative is expected to provide a new therapeutic option for patients suffering from a currently incurable condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from StemRIM
- StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
- Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]
Later from StemRIM
- StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in,South Korea
- StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
- StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
- StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
Follow StemRIM into a list and get an email when it puts out news.
Follow StemRIM